Nucleus RadioPharma and Perceptive Discovery Partner to Accelerate Radiopharmaceutical Development

Nucleus RadioPharma and Perceptive Discovery have announced a strategic partnership aimed at streamlining the development process for radiopharmaceuticals, from early target validation through to clinical manufacturing. The collaboration merges Perceptive Discovery's expertise in preclinical molecular imaging, radiochemistry, and biodistribution studies with Nucleus RadioPharma's GMP-compliant radiolabeling, process development, and clinical manufacturing capabilities.

The agreement intends to significantly reduce the time, costs, and friction typically encountered when advancing radiopharmaceutical candidates from imaging studies to industrial-scale production. The companies will refer qualified customers to each other across the development continuum, establishing an integrated pathway from promising discoveries to patient accessibility. This approach ensures that manufacturability and scalability are considered from the early stages of development, which is crucial for faster market entry of new therapies.

Through this partnership, Perceptive Discovery extends its services towards clinical manufacturing, while Nucleus RadioPharma gains access to Perceptive Discovery's preclinical research expertise. Both companies emphasize that customer choice remains paramount, and the collaboration is designed to scale according to client needs.